Aroa's study is showing Myriad success in lower limb reconstruction Pic: via Getty Images
Health & Biotech
Special Report: Aroa’s latest study reveals potential of its Myriad treatment range in saving limbs and reducing costs, making it a potential game-changer for high-risk lower limb surgeries.
Aroa Biosurgery (ASX: ARX) has announced the publication of the first results from its Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), which has shown significant promise in treating high-risk lower limb reconstruction cases.
The peer-reviewed real-world research is titled “Limb Salvage via Surgical Soft Tissue Reconstruction with Ovine Forestomach Matrix Graft: A Prospective Study”.
It’s the largest study of lower limb reconstructions with a dermal substitute, showing strong efficacy for the company’s extracellular matrix graft, Myriad.
The study, published in the December issue of Plastic and Reconstructive Surgery – Global Open, marks a key milestone for Aroa, and reinforces the growing potential of Myriad in the surgical limb salvage market.
The study was conducted between May 2022 and April 2023 and involved 130 lower limb defects across 120 patients.
Of these patients, 95% had at least one risk factor for amputation, and 55% had three or more predictive risk factors for amputation.
Lower limb amputation, as we know, can severely impact quality of life, and the five-year mortality rate for patients receiving this amputation can be up to ~50%.
The study found that Myriad Matrix and Myriad Morcells achieved 100% tissue coverage and fill in just 30 days, with only a single application – and crucially, no infections or complications.
The study not only confirms the clinical efficacy of Myriad in lower limb reconstruction procedures, but also highlights significant cost-saving potential.
It demonstrated a cost difference of up to 195% compared to other commercially available dermal substitutes suggesting that Myriad can be a cost-efficient solution for complex lower limb surgeries, where cost containment is a growing priority.
“We are very pleased to see the first clinical evidence emerge from our large prospective MASTRR study,” said Brian Ward, founder and CEO of Aroa.
“The evidence from this study further validates both the efficacy of, and potential cost benefits associated with Myriad use in lower limb reconstruction procedures.
“With a total addressable market of US$225 million for lower limb procedures alone, this represents a considerable opportunity for Aroa.”
This publication comes at a crucial time, as lower limb amputation remains a serious health challenge.
The five-year mortality rate for patients who undergo such amputations can be as high as 50%, and the costs of care for patients with diabetic foot complications are comparable to those of cancer.
Myriad’s potential to address these complex cases is further underlined by the fact that it is designed for rapid tissue reconstruction, which is key to saving limbs and enhancing patient outcomes.
Aroa’s Myriad range, developed from ovine (sheep) forestomach matrix, provides a unique scaffold for tissue regeneration, aiding in faster and more efficient healing.
With its dense network of vascular channels and over 150 healing proteins, the extracellular matrix (ECM) mimics the structure of human skin and supports the body’s natural regenerative processes.
According to Dr Brandon Bosque, Aroa’s medical science liaison, lower extremity reconstruction can be particularly challenging due to the nature of the defects and the patient cohort affected.
However, a 2023 study of Myriad’s use in 50 cases of complex lower limb defects found that the product was safe, cost-effective and clinically efficacious.
This article was developed in collaboration with Aroa Biosurgery, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Health & Biotech
Health & Biotech
Health & Biotech
